Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study

Aniek Uittenboogaard; Mirjam van de Velde; Lisa van de Heijden; Leah Mukuhi; Niels de Vries; Sandra Langat; Gilbert Olbara; Alwin D. R. Huitema; Terry Vik; Gertjan Kaspers; Festus Njuguna

doi:10.1002/pbc.31160

Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study

Aniek Uittenboogaard^*
, Mirjam van de Velde
, Lisa van de Heijden
, Leah Mukuhi
, Niels de Vries
, Sandra Langat
, Gilbert Olbara
, Alwin D. R. Huitema
, Terry Vik
, Gertjan Kaspers
, Festus Njuguna

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

12 Downloads (Pure)

Abstract

The low incidence of vincristine-induced peripheral neuropathy (VIPN) in Kenyan children may result from low vincristine exposure. We studied vincristine exposure in Kenyan children and dose-escalated in case of low vincristine exposure (NCT05844670). Average vincristine exposure was high. Individual vincristine exposure was assessed with a previously developed nomogram. A 20% dose increase was recommended for participants with low exposure and no VIPN, hyperbilirubinemia, or malnutrition. None of the 15 participants developed VIPN. Low vincristine exposure was seen in one participant: a dose increase was implemented without side effects. In conclusion, the participants did not develop VIPN despite having high vincristine exposure.

Original language	English
Article number	e31160
Journal	Pediatric Blood and Cancer
Volume	71
Issue number	9
DOIs	https://doi.org/10.1002/pbc.31160
Publication status	Published - 1 Sept 2024

Keywords

feasibility study
individualized dosing
pediatric oncology
pharmacokinetics
sub-Saharan Africa
vincristine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/pbc.31160

Vincristine-exposure-in-kenyan-children-with-cancer.pdfFinal published version, 379 KB

Cite this

@article{d97f44e362fc447baaab5515b3f4a5ee,

title = "Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study",

abstract = "The low incidence of vincristine-induced peripheral neuropathy (VIPN) in Kenyan children may result from low vincristine exposure. We studied vincristine exposure in Kenyan children and dose-escalated in case of low vincristine exposure (NCT05844670). Average vincristine exposure was high. Individual vincristine exposure was assessed with a previously developed nomogram. A 20\% dose increase was recommended for participants with low exposure and no VIPN, hyperbilirubinemia, or malnutrition. None of the 15 participants developed VIPN. Low vincristine exposure was seen in one participant: a dose increase was implemented without side effects. In conclusion, the participants did not develop VIPN despite having high vincristine exposure.",

keywords = "feasibility study, individualized dosing, pediatric oncology, pharmacokinetics, sub-Saharan Africa, vincristine",

author = "Aniek Uittenboogaard and \{van de Velde\}, Mirjam and \{van de Heijden\}, Lisa and Leah Mukuhi and \{de Vries\}, Niels and Sandra Langat and Gilbert Olbara and Huitema, \{Alwin D. R.\} and Terry Vik and Gertjan Kaspers and Festus Njuguna",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Pediatric Blood \& Cancer published by Wiley Periodicals LLC.",

year = "2024",

month = sep,

day = "1",

doi = "10.1002/pbc.31160",

language = "English",

volume = "71",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "9",

}

TY - JOUR

T1 - Vincristine exposure in Kenyan children with cancer

T2 - CHAPATI feasibility study

AU - Uittenboogaard, Aniek

AU - van de Velde, Mirjam

AU - van de Heijden, Lisa

AU - Mukuhi, Leah

AU - de Vries, Niels

AU - Langat, Sandra

AU - Olbara, Gilbert

AU - Huitema, Alwin D. R.

AU - Vik, Terry

AU - Kaspers, Gertjan

AU - Njuguna, Festus

PY - 2024/9/1

Y1 - 2024/9/1

N2 - The low incidence of vincristine-induced peripheral neuropathy (VIPN) in Kenyan children may result from low vincristine exposure. We studied vincristine exposure in Kenyan children and dose-escalated in case of low vincristine exposure (NCT05844670). Average vincristine exposure was high. Individual vincristine exposure was assessed with a previously developed nomogram. A 20% dose increase was recommended for participants with low exposure and no VIPN, hyperbilirubinemia, or malnutrition. None of the 15 participants developed VIPN. Low vincristine exposure was seen in one participant: a dose increase was implemented without side effects. In conclusion, the participants did not develop VIPN despite having high vincristine exposure.

AB - The low incidence of vincristine-induced peripheral neuropathy (VIPN) in Kenyan children may result from low vincristine exposure. We studied vincristine exposure in Kenyan children and dose-escalated in case of low vincristine exposure (NCT05844670). Average vincristine exposure was high. Individual vincristine exposure was assessed with a previously developed nomogram. A 20% dose increase was recommended for participants with low exposure and no VIPN, hyperbilirubinemia, or malnutrition. None of the 15 participants developed VIPN. Low vincristine exposure was seen in one participant: a dose increase was implemented without side effects. In conclusion, the participants did not develop VIPN despite having high vincristine exposure.

KW - feasibility study

KW - individualized dosing

KW - pediatric oncology

KW - pharmacokinetics

KW - sub-Saharan Africa

KW - vincristine

UR - https://www.scopus.com/pages/publications/85197250501

U2 - 10.1002/pbc.31160

DO - 10.1002/pbc.31160

M3 - Article

C2 - 38956809

SN - 1545-5009

VL - 71

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 9

M1 - e31160

ER -

Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this